Lung cancer remains the leading cause of cancer deaths worldwide and is the most common cancer in males.Immune-checkpoint inhibitors(ICIs)that target programmed cell death protein-1(PD-1)or programmed cell death-ligan...Lung cancer remains the leading cause of cancer deaths worldwide and is the most common cancer in males.Immune-checkpoint inhibitors(ICIs)that target programmed cell death protein-1(PD-1)or programmed cell death-ligand 1(PD-L1)have achieved impressive efficacy in the treatment of non-small-cell lung cancer(NSCLC)(Pardoll,2012;Champiat et al.,2016;Gao et al.,2022).Although ICIs are usually well tolerated,they are often accompanied by immune-related adverse events(irAEs)(Doroshow et al.,2019).Non-specific activation of the immune system produces off-target immune and inflammatory responses that can affect virtually any organ or system(O'Kane et al.,2017;Puzanov et al.,2017).展开更多
文摘Lung cancer remains the leading cause of cancer deaths worldwide and is the most common cancer in males.Immune-checkpoint inhibitors(ICIs)that target programmed cell death protein-1(PD-1)or programmed cell death-ligand 1(PD-L1)have achieved impressive efficacy in the treatment of non-small-cell lung cancer(NSCLC)(Pardoll,2012;Champiat et al.,2016;Gao et al.,2022).Although ICIs are usually well tolerated,they are often accompanied by immune-related adverse events(irAEs)(Doroshow et al.,2019).Non-specific activation of the immune system produces off-target immune and inflammatory responses that can affect virtually any organ or system(O'Kane et al.,2017;Puzanov et al.,2017).
